The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Splice-Modulating Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A>G LCA10 Models
Open accessAbstract
Leber congenital amaurosis type 10 (LCA10) is a severe inherited retinal dystrophy associated with mutations in CEP290. The deep intronic c.2991+1655A>G mutation in CEP290 is the most common mutation in LCA10 individuals and represents an ideal target for oligonucleotide therapeutics. Here, a panel of antisense oligonucleotides was designed to correct the splicing defect associated with the mutation and screened for efficacy and safety. This identified QR-110 as the best-performing molecule. QR-110 restored wild-type CEP290 mRNA and protein expression levels in CEP290 c.2991+1655A>G homozygous and compound heterozygous LCA10 primary fibroblasts. Furthermore, in homozygous three-dimensional iPSC-derived retinal organoids, QR-110 showed a dose-dependent restoration of mRNA and protein function, as measured by percentage and length of photoreceptor cilia, without off-target effects. Localization studies in wild-type mice and rabbits showed that QR-110 readily reached all retinal layers, with an estimated half-life of 58 days. It was well tolerated following intravitreal injection in monkeys. In conclusion, the pharmacodynamic, pharmacokinetic, and safety properties make QR-110 a promising candidate for treating LCA10, and clinical development is currently ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Self-formation of optic cups and storable stratified neural retina from human ESCs
Nakano, T., Ando, S., Takata, N., Kawada, M., Muguruma, K., Sekiguchi, K., Saito, K., Yonemura, S., Eiraku, M., & Sasai, Y. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.05.009 · Cited by 1,447 · cited 3×
“Directed differentiation of iPSCs into 3D retinal organoids was based on the protocol by Nakano et al.50 Table S3 summarizes the different media used for differentiation. iPSCs were dissociated using TrypLE (Life Technologies) and plated at a density of 9,000 cells per well in V-shaped 96-well plates in E8 supplemente…”
MethodEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Leber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Safety evaluation of ocular drug delivery formulations: Techniques and practical considerations
Short, B. G. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310955 · Cited by 244
Visual Acuity after Retinal Gene Therapy for Choroideremia
Edwards, T. L., Jolly, J. K., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509501 · Cited by 195
Zhang, W., Li, L., Su, Q., Gao, G., & Khanna, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.049 · Cited by 60 · cited 1×
“smaller fragments to be used.(31) Although intronic mutations, such as in CEP290 c.”
Background
Cited by
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
Self-citationBuilding Models of Brain Disorders with Three-Dimensional Organoids
Amin, N. D., & Paşca, S. P. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.007 · Cited by 312
Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & Collaborative, N. =. 1. (2024) · Communications Medicine · doi:10.1038/s43856-023-00419-1 · Cited by 273
Pluripotent stem cell-derived retinal organoids for disease modeling and development of therapies
Kruczek, K., & Swaroop, A. (2020) · Stem Cells · doi:10.1002/stem.3239 · Cited by 148
“defects in retinal organoids and RPE cells derived from a patient with a common intronic mutation in the CEP290 gene.(44,58)”
Background
Metadata
- Authors
- Dulla, K., Aguila, M., Lane, A., Jovanovic, K., Parfitt, D. A., Schulkens, I., Chan, H. L., Schmidt, I., Beumer, W., Vorthoren, L., Collin, R. W. J., Garanto, A., Duijkers, L., Brugulat-Panes, A., Semo, M., Vugler, A. A., Biasutto, P., Adamson, P., & Cheetham, M. E.
- Venue
- Molecular Therapy Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 12
- Pages
- 730-740
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2883897094
- Cited by
- 165
- References
- 9
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.